Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18733545 | CORONAVIRUS VACCINE COMPRISING A MOSAIC PROTEIN | June 2024 | March 2026 | Allow | 21 | 3 | 1 | No | No |
| 18154278 | RECOMBINANT ARTERIVIRUS REPLICON SYSTEMS AND USES THEREOF | January 2023 | September 2024 | Allow | 20 | 1 | 0 | No | No |
| 17924800 | REDIRECTION OF TROPISM OF AAV CAPSIDS | November 2022 | March 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17997595 | METHODS TO DETECT A VIRUS IN A BIOLOGICAL SAMPLE | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17970814 | METHODS OF DETECTING ANTIBODIES TO SARS-COV-2 | October 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17920772 | Lateral Flow Device for Detection of Neutralizing Antibodies Against SARS-COV-2 | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17995546 | VACCINES, ADJUVANTS, AND METHODS OF GENERATING AN IMMUNE RESPONSE | October 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17908916 | NOVEL CORONAVIRUS S PROTEIN DOUBLE-REGION SUBUNIT NANO-VACCINE BASED ON BACTERIAL COMPLEX | September 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17898870 | PHOSPHATE-REGULATED EXPRESSION OF BIOLOGICALLY ACTIVE RECOMBINANT CORONAVIRUS GLYCOPROTEINS AND OTHER RECOMBINANT PROTEINS IN PHAEODACTYLUM TRICORNUTUM | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17798021 | SARS-COV-2 VACCINE | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17789652 | QUANTITATIVE PCR SCREENING OF INDUCIBLE PROPHAGE FROM BACTERIAL ISOLATES | June 2022 | February 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17827451 | NEW SALIVA-BASED LATERAL-FLOW ANTIBODY TEST PLATFORM FOR ASSESSING INFECTIONS AND VACCINATION EFFICACY | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17735415 | DIAGNOSTIC TEST FOR VACCINE VALIDATION AND AUTHENTICATION AND METHODS OF USE THEREOF | May 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17726110 | SARS-COV-2 SUBUNIT AND VARIANT VACCINES | April 2022 | January 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17720334 | METHOD FOR PREPARING ATOMIZING SARS-COV-2 NANOVACCINE | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17631528 | Elisa Method as an Alternative to Neutralization Potency Assay and Use Thereof | March 2022 | October 2025 | Abandon | 52 | 1 | 0 | No | No |
| 17589427 | IMMUNOMODULATION PLATFORM AND METHODS OF USE | January 2022 | October 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17560830 | ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION, AND COMPOSITIONS, COMBINATIONS AND METHODS FOR USE THEREOF | December 2021 | August 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17619316 | METHOD FOR PURIFYING VIRUS OR VIRUS-LIKE PARTICLE | December 2021 | November 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17618122 | RATIONALLY ENGINEERED CARRIER PROTEINS FOR VACCINES | December 2021 | January 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17512027 | Anti-Viroporin Antibodies and Methods of Treating COVID-19 | October 2021 | January 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17603331 | A RECOMBINANT HTLV-1 VACCINE | October 2021 | February 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17602532 | Chimeric Zika-Japanese Encephalitis Virus | October 2021 | October 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17491568 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CORONAVIRUS DISEASE 2019 | October 2021 | October 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17447348 | METHOD FOR PREPARING A BIOLOGICAL SAMPLE AND FOR DETECTING BIOLOGICAL SPECIES PRESENT IN THE BIOLOGICAL SAMPLE | September 2021 | October 2025 | Abandon | 49 | 2 | 0 | No | No |
| 16623205 | PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND FORMULATIONS THEREOF FOR TREATMENT OF SYNUCLEINOPATHIES | December 2019 | May 2023 | Allow | 41 | 6 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner BUCKMASTER, MARLENE VRENI works in Art Unit 1672 and has examined 10 patent applications in our dataset. With an allowance rate of 20.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner BUCKMASTER, MARLENE VRENI's allowance rate of 20.0% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BUCKMASTER, MARLENE VRENI receive 2.00 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BUCKMASTER, MARLENE VRENI is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +66.7% benefit to allowance rate for applications examined by BUCKMASTER, MARLENE VRENI. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.